Blue Cross Blue Shield · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Diagnosis confirmed by lab tests (e.g., A1C ≥6.5%).

Source policy: Blue Cross Blue Shield tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Blue Cross Blue Shield angle on Tirzepatide

## BCBS Step-Therapy Denials for Tirzepatide (Mounjaro/Zepbound): The Mechanic and the Override

Blue Cross Blue Shield plans — whether Anthem BCBS (Carelon-administered behavioral, Express Scripts or CarelonRx pharmacy depending on state), BCBS Texas/Illinois/Montana/New Mexico/Oklahoma (HCSC, Prime Therapeutics PBM, Magellan behavioral), Highmark BCBS (Express Scripts), or Independence Blue Cross (FutureScripts/OptumRx) — all funnel tirzepatide through a step-therapy edit before approving Mounjaro for T2DM or Zepbound for obesity. The mechanic is nearly identical across BCBSA licensees: the member must demonstrate prior trial-and-failure, intolerance, or contraindication to metformin plus at least one additional preferred GLP-1 (typically semaglutide/Ozempic, dulaglutide/Trulicity, or liraglutide/Victoza) before tirzepatide is dispensed at the preferred tier. The criterion you received — "A1C ≥6.5% confirmed by lab" — is only the diagnostic gate; it does not satisfy the step edit.

The step-therapy denial is overrideable, but BCBS will not volunteer the lever. Under 29 USC §1185d (added by the Consolidated Appropriations Act provisions reinforcing the No Surprises and parity framework) and analogous state step-therapy override statutes — now enacted in 36+ states including Texas Ins. Code §1369.0546, Illinois 215 ILCS 134/45.2, and New York Ins. Law §4903 — the plan must grant an exception when any of five clinical conditions is documented: (1) the required preferred drug is contraindicated; (2) expected to be ineffective based on the patient's clinical characteristics; (3) previously tried under any insurer and discontinued for lack of efficacy or adverse effect; (4) the patient is stable on the requested drug; or (5) the required drug is not in the patient's best interest. Critically, prior trials under a previous insurer count — BCBS routinely denies on "no documented step within our claims history," which is legally insufficient when the prescriber attests to prior semaglutide failure documented in chart notes.

For commercial BCBS plans, escalate via the plan's medical policy (e.g., Anthem CG-DRUG-130 / Pharmacy Policy 0006; BCBSTX Rx Step Therapy Criteria; Highmark MP P-9999) — cite the exact policy number on the appeal. For ERISA-governed plans, 29 CFR §2560.503-1(h)(3)(iii) requires the plan to identify the specific clinical rationale and the qualifications of the reviewer; demand the reviewer's specialty (endocrinology, not a generalist). If denied a second time, file a simultaneous external review under your state DOI's IRO process — the 45 CFR §156.122 formulary-exceptions standard applies to ACA marketplace BCBS plans and gives a 72-hour standard / 24-hour expedited turnaround.

Tactical tip: Attach a one-page "step-therapy override attestation" signed by the prescriber that explicitly invokes the state statute by section number, lists prior GLP-1 trials with dates/doses/adverse events (even self-pay or sample trials), and cites contraindication to sulfonylureas or insulin if applicable. BCBS auto-adjudication systems flag attestations citing the state statute for human review rather than reflex denial.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other insurers on Tirzepatide

Other denial reasons for Blue Cross Blue Shield Tirzepatide

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.